Genotoxicity of therapeutic intervention in children with acute lymphocytic leukemia

Cancer Research
Sederick C RiceB A Finette

Abstract

The survival rates of children treated for cancer have dramatically increased after the development of standardized multiple-modality treatment protocols. As a result, there is a rapidly growing population of pediatric cancer survivors in which the long-term genotoxic effects of chemotherapeutic intervention is unknown. To study the genotoxic effects of antineoplastic treatment in children, we performed a comparative analysis of the changes in the frequency of somatic mutations (Mfs) at the hypoxanthine-guanine phosphoribosyltransferase (HPRT)-reporter gene in children treated for acute lymphocytic leukemia (ALL). We measured HPRT Mfs from 130 peripheral blood samples from 45 children with ALL (13, low risk; 22, standard risk; and 10, high risk) from the time of diagnosis, as well as during and after the completion of therapy. We observed a significant increase in mean HPRT Mfs during each phase of therapy (diagnosis, 1.4 x 10(-6); consolidation, 52.1 x 10(-6); maintenance, 93.2 x 10(-6); and off-therapy, 271.7 x 10(-6)) that were independent of the risk group treatment protocol used. This 200-fold increase in mean somatic Mf remained elevated years after the completion of therapy. We did not observe a significant difference in...Continue Reading

References

Sep 1, 1988·Mutation Research·M HakodaM Otake
Jan 1, 1985·Annual Review of Genetics·J T Stout, C T Caskey
Nov 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·R J AlbertiniW R Borcherding
Jan 1, 1997·Environmental and Molecular Mutagenesis·A D da Cruz, B W Glickman
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V M Kimball DaltonS E Sallan
Mar 17, 1999·Clinical Immunology : the Official Journal of the Clinical Immunology Society·M T FaltaR J Albertini
Apr 25, 2000·Science·B A FinetteR J Albertini
Apr 20, 2001·Journal of the National Cancer Institute·J P NegliaL L Robison
Aug 15, 2002·Mutation Research·Barry A FinettePamela M Vacek
Nov 15, 2002·Pediatric Clinics of North America·Debra L Friedman, Anna T Meadows
Feb 25, 2003·Cancer·Lihua LiuUNKNOWN Surveillance, Epidemiology and End Results Childhood Cancer Linkage Group
Jul 23, 2003·Environmental and Molecular Mutagenesis·Sederick C RiceBarry A Finette
Jul 25, 2003·British Journal of Haematology·Leslie L Robison, Smita Bhatia
Aug 15, 2003·The New England Journal of Medicine·Ching-Hon PuiMelissa M Hudson

❮ Previous
Next ❯

Citations

Jul 24, 2002·Seminars in Roentgenology·Elma Abella-Columna, Peter E Valk
May 23, 2001·Critical Reviews in Oncology/hematology·J N TalbotF Montravers
Jul 20, 2010·Oncogene·M M Lovric, C J Hawkins
Apr 29, 2014·Bulletin of Experimental Biology and Medicine·E N ArkhipovaM Yu Karganov
Mar 5, 2016·Mutation Research·Mark A MilesChristine J Hawkins
Sep 29, 2004·Drug Discovery Today·Jo Whelan
Sep 15, 2004·Lancet·Ching-Hon Pui, Mary V Relling
Apr 18, 2008·Environmental and Molecular Mutagenesis·Irene M JonesDavid O Nelson
Jun 13, 2009·Blood·Nanne K H de BoerAdriaan A van Bodegraven
Dec 20, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Guillaume CartronHolbrook E Kohrt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.